Inactive Instrument

Highlights Nanomix Corporation

Equities

NNMX

US63008H2013

Advanced Medical Equipment & Technology

Highlights

23-11-24	Nanomix Corporation Announces Chief Executive Officer Changes	CI
23-04-07	Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-01-25	Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial Officer	CI
22-11-29	Nanomix Corporation Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy	CI
22-11-14	Nanomix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-11-09	Nanomix Corporation Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd	CI
22-11-04	Nanomix Corporation Enters into Multi-Country Distribution Agreement for the Elab System with Mast Group Limited	CI
22-10-20	Nanomix Corporation Announces Distribution Agreement with Diaclinic SpA	CI
22-09-12	Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Ips Genomix S.A.L. in the Middle East	CI
22-09-02	Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies	CI
22-08-23	Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Bioasia Pte Ltd in Singapore	CI
22-08-15	Nanomix Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
22-07-21	Nanomix Corporation Announces Distribution Agreement for the eLab System with Biotron Ltd. in Israel	CI
22-06-22	Nanomix Corporation Initiates New Clinical Study for the eLab S1 Panel	CI
22-06-14	Nanomix Corporation Receives IVDR Certification for the eLab Analyzer	CI
22-05-26	Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood Samples	CI
22-05-17	Nanomix Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
21-12-08	Nanomix Announces UK MHRA Registration for New Point of Care System	CI
21-12-01	Nanomix Corporation Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19	CI
21-08-27	Boston Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021	CI
21-08-27	Boston Therapeutics, Inc. Announces Audited Consolidated Earnings Results for the Full Year Ended December 31, 2020	CI
21-06-14	Boston Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
21-06-03	Nanomix, Inc. completed the acquisition of Boston Therapeutics, Inc. in a reverse merger transaction on June 4, 2021.	CI
21-04-23	Boston Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
21-02-01	Nanomix, Inc. entered into an Agreement to acquire Boston Therapeutics, Inc. in a reverse merger transaction.	CI